The mission of the Greenville SC CCOP is to make vital contributions to the National Cancer Institutes'goal of """"""""eliminating suffering and death from cancer by the year 2015,"""""""" and to bring this goal home to our community in Upstate Carolina. We will be supportive of the NCI, all inclusive in our approach towards seeking ethical investigators and willing participants. To meet this goal, our specific objectives are the following: 1. To enroll eligible, consenting subjects to treatment, prevention and symptom management trials. 2. To ensure that correlative science and quality of life research is integrated in the research processes as appropriate. 3. To maintain protocol compliance and to report on the subject through accurate, timely data submissions. 4. To work with our community IRB to protect subjects through a streamlined process. Cancer patients suffer due to their disease as well as their treatment. The goal of our mission is to reduce death, pain and suffering, no matter the source. The techniques to achieve this goal are to follow specific procedures to protect, enroll and report on our research patients. To meet these goals our research team, consisting of a core group of 15 actively enrolling investigators and a dedicated research staff of 20, has developed a defined process to ethically treat research subjects. Patients are identified by oncologists, referring physicians or via outreach activities. Standard operating procedures and quality assurance procedures provide guidance to ensure the subject is eligible, treated according to the protocol and reported on accurately. There is a persistant opportunity to improve on these procedures. Monthly meetings bring together the investigators and research staff as well as ancillary staff and provide the avenue for oversight. We acknowledge that tissue banking and quality of life data is essential towards improving the care of our patients, and all research staff have been trained on the importance of this aspect of our mission. The institutional review board serves all affiliate hospitals which assists to streamline the process. Good clinical practices education is provided by the Office of Research Compliance of Greenville Hospital System and works to assist all parties on the regulations of human safety protection.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-3 (J1))
Program Officer
O'Mara, Ann M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Oncology & Hematology Associates of SC
United States
Zip Code
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8
Persky, Daniel O; Miller, Thomas P; Unger, Joseph M et al. (2015) Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood 125:236-41
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Advani, Anjali S; McDonough, Shannon; Coutre, Steven et al. (2014) SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol 165:504-9
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8
Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51
Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8

Showing the most recent 10 out of 95 publications